Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-900-4520
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) posted its earnings results on Thursday, March, 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.10. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 analysts have issued 1 year price targets for Corvus Pharmaceuticals' shares. Their forecasts range from $11.00 to $17.00. On average, they anticipate Corvus Pharmaceuticals' share price to reach $14.3333 in the next year. This suggests a possible upside of 225.8% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
Media headlines about CRVS stock have trended neutral recently, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a news sentiment score of 0.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the stock's share price in the near term.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Arcus Biosciences (RCUS), Assembly Biosciences (ASMB), ZEALAND PHARMA/S (ZEAL), BioSpecifics Technologies (BSTC), NuCana (NCNA), Zymeworks (ZYME), CytomX Therapeutics (CTMX), Corbus Pharmaceuticals (CRBP), Kalvista Pharmaceuticals (KALV), Dynavax Technologies (DVAX), Cytokinetics (CYTK), Five Prime Therapeutics (FPRX), Akebia Therapeutics (AKBA), Corium International (CORI) and Flexion Therapeutics (FLXN).
What other stocks do shareholders of Corvus Pharmaceuticals own?
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
- Mr. Leiv Lea, Chief Financial Officer (Age 65)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
- Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (3.56%), BlackRock Inc. (3.23%), Dimensional Fund Advisors LP (1.15%), Dimensional Fund Advisors LP (1.15%), Puissance Capital Management LP (0.97%) and Fosun International Ltd (0.54%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo, Leiv Lea and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which major investors are selling Corvus Pharmaceuticals stock?
Which major investors are buying Corvus Pharmaceuticals stock?
CRVS stock was purchased by a variety of institutional investors in the last quarter, including Puissance Capital Management LP, Fosun International Ltd, Telemetry Investments L.L.C., Hikari Power Ltd, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Two Sigma Investments LP and Geode Capital Management LLC. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Holdings A/S Novo, Leiv Lea and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $4.40.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $129.04 million.
What is Corvus Pharmaceuticals' official website?
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
